Your browser doesn't support javascript.
loading
Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
Obici, Laura; Berk, John L; González-Duarte, Alejandra; Coelho, Teresa; Gillmore, Julian; Schmidt, Hartmut H-J; Schilling, Matthias; Yamashita, Taro; Labeyrie, Céline; Brannagan, Thomas H; Ajroud-Driss, Senda; Gorevic, Peter; Kristen, Arnt V; Franklin, Jaclyn; Chen, Jihong; Sweetser, Marianne T; Wang, Jing Jing; Adams, David.
Afiliação
  • Obici L; Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Berk JL; Amyloidosis Center, Boston Medical Center, Boston, MA, USA.
  • González-Duarte A; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Coelho T; Hospital de Santo António, Centro Hospitalar do Porto, Porto, Portugal.
  • Gillmore J; Division of Medicine, National Amyloidosis Centre, University College London, London, UK.
  • Schmidt HH; Medical Clinic for Gastroenterology and Hepatology, University of Münster, Münster, Germany.
  • Schilling M; Department of Neurology, Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Yamashita T; Department of Neurology, Kumamoto University, Kumamoto, Japan.
  • Labeyrie C; Assistance Publique-Hôpitaux de Paris (APHP), French National Reference Center for Familial Amyloidotic Polyneuropathy, Centre Hospitalier Universitaire Bicêtre, Universite Paris-Sud, INSERM Unite, Paris, France.
  • Brannagan TH; Department of Neurology, Columbia University Medical Center, New York, NY, USA.
  • Ajroud-Driss S; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Gorevic P; Department of Medicine, Mount Sinai Medical Center, New York, NY, USA.
  • Kristen AV; Department of Cardiology, University of Heidelberg, Heidelberg, Germany.
  • Franklin J; Alnylam Pharmaceuticals, Cambridge, MA, USA.
  • Chen J; Alnylam Pharmaceuticals, Cambridge, MA, USA.
  • Sweetser MT; Alnylam Pharmaceuticals, Cambridge, MA, USA.
  • Wang JJ; Alnylam Pharmaceuticals, Cambridge, MA, USA.
  • Adams D; Assistance Publique-Hôpitaux de Paris (APHP), French National Reference Center for Familial Amyloidotic Polyneuropathy, Centre Hospitalier Universitaire Bicêtre, Universite Paris-Sud, INSERM Unite, Paris, France.
Amyloid ; 27(3): 153-162, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32131641
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polineuropatias / Pré-Albumina / Neuropatias Amiloides Familiares / RNA Interferente Pequeno Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Polineuropatias / Pré-Albumina / Neuropatias Amiloides Familiares / RNA Interferente Pequeno Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article